CMS (Centers for Medicare and Medicaid Services) set to review LVADs, burns reimbursement rates
This article was originally published in Clinica
The Centers for Medicare & Medicaid Services is contemplating raising the reimbursement rate for left ventricular assist devices intended for permanent implantation. The agency announced this week that it would like to reassign LVADs intended for such destination therapy to DRG (diagnosis related group) 103, now used for heart transplants.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.